KMI is the better play. $1 decline in the price of oil per barrel equates to a $7 million decline in the company's cash flow -- a drop in the bucket for a company with over $4 billion in operating cash flow last year. only 15% of its asset base really exposed to crude price changes, it is more insulated than most. With a $2.00 per share dividend targeted for 2015, the stock would yield more than 5% based on the current share price.
According to the annual report filed by BGMD, 8.7 million shares belong to Entities affiliated with Flagship Ventures. Noubar was deemed to be the Beneficial owner for SEC purposes. He just transferred to his partner, Edward Kania, of Flagship Ventures, his due portion of the shares not on the open market for 0 dollars per share recently. Now they have 9.9 million combined. Keep up the good work!
The timing of this move is interesting.
Very well put. It really is all about the FDA at this point. Reminds me of giving my friend a hard time about buying PLUG at .26, especially when it traded down from like 2.30ish to .12 in a years time. GLTU
Noubar had owned 8,186,182 shares. Now he owns 4,840,775 shares (Indirect) and 175,718 shares (Direct) for a total of 5,016,493. Kania Edwin M Jr. now owns 5,549,792 shares (Indirect). A total of 10,566,285 shares between the two now.
2,484,192 transferring of shares not on the open market for $0 a per share.
703,655 transferring of shares not on the open market for $0 a per share.
98,570 transferring of shares not on the open market for $0 a per share.
98,352 transferring of shares not on the open market for $0 a per share.
(Remember, Kania Edwin M Jr was also granted 634,390 shares)
Kania Edwin was not a BGMD insider nor a 10% owner so he wouldn't have had to report owning any previous shares directly or indirectly.
Looks like he might have had about 1.5 million shares indirectly.
Insiders own 12.77 million shares now at 37 percent. Hope this helps some.
Check out ownership on Yahoo finance and holdings NASDAQ for BGMD
A lot of shares are trading hands among businesses Noubar Afeyan and Edwin M. Kania, Jr have a
NewcoGen Group, Inc. ("NG") is the manager of each of NewcoGen Group LLC ("NGG"), NewcoGen Equity Investors LLC ("NEI") and NewcoGen-Long Reign Holding LLC ("NGLRH", and together with NGG and NEI, the "NewcoGen Funds"). NG is also the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. ("AGTCA") and Applied Genomic Technology Capital Fund L.P. ("AGTCF", and together with AGTCA, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar Afeyan and Edwin M. Kania, Jr. are directors of Flagship and may be deemed to beneficially own the securities held by the NewcoGen Funds and the AGTC Funds. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein
Although for purposes of determining status as a ten percent holder, a person is deemed to beneficially own securities over which that person exercises voting or investment control (see Rule 16a-1(a)(1)), for reporting transactions and holdings, a person is deemed to be the beneficial owner of securities if that person has the opportunity, directly or indirectly, to profit or share in any profit derived from a transaction in the securities (“pecuniary interest”). See Rule 16a-1(a)(2). See also Rule 16a-8 for the application of the beneficial ownership definition to trust holdings and transactions.
D – Sale (or disposition) back to the issuer of the securities. Maybe they borrowed the shares to short the stock and now they are returning them since covering? (Joke)
Seems like a lot of shares are trading hands among businesses Noubar Afeyan and Edwin M. Kania, Jr have a financial interest in. Nothing negative in the filings in my opinion. Looks like some sort of tax strategy for something major about to happen. GLTA.
NewcoGen Group, Inc. ("NG") is the manager of each of NewcoGen Group LLC ("NGG"), NewcoGen Equity Investors LLC ("NEI") and NewcoGen-Long Reign Holding LLC ("NGLRH", and together with NGG and NEI, the "NewcoGen Funds"). NG is also the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. ("AGTCA") and Applied Genomic Technology Capital Fund L.P. ("AGTCF", and together with AGTCA, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar Afeyan and Edwin M. Kania, Jr. are directors of Flagship and may be deemed to beneficially own the securities held by the NewcoGen Funds and the AGTC Funds. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.
You get 6 months notice before delisting. Then you can ask for six month extension. You get appeals and hearing. Whole process could take over a year once notice is given. Plenty of time to get back over a dollar or sell Company. Should be a none factor in investing decisions at this point.
Doing the opposite of what they say with SD has been a good trade. Buy when they say sell, and sell when they say buy.
Doug, you might want to read up on the oil crisis of 1998. This looks like a very similar play by the Saudis to force cuts by everyone. Not just cuts on future drilling projects. But cuts on current drilling. Going to need some more pain for that.
Calm down and relax. I have been following this stock for quite sometime and haven't seen him post lately. Just checking up with what he is up to.
75% of its oil production for 2015 is hedged. So it should be a 34% discount of BV of 3.41 of unhedged oil production. So how much revenue is from SD unhedged oil production on a percentage basis?
I would say so. I find it hard to believe that the company would not fetch at least 3 on a buyout instead of bankruptcy
SandRidge is better hedged to lower oil prices than are most of its small-cap energy peers, and that it has relatively less debt as well.
"Welcome to the new world of oil," said Michael Wittner, senior oil analyst at French bank Societe Generale. "Saudi Arabia and OPEC will no longer be the mechanism to balance the market, they have relinquished that role."
"Instead, the market itself – prices, in other words – will be the mechanism to rebalance the market. We cannot overstate what a dramatic and fundamental change this is for the oil market," he added.
Brent was headed for its steepest monthly decline since November 2008, after falling more than 15 percent this month.
It has lost more than a third of its value since June, falling from above $115 a barrel as increasing shale output in North America has helped create a glut at a time of sluggish global economic growth.
"The market is looking for a new paradigm, a new range to settle into. Where that is, is anybody’s guess. It could be $60, $70, or maybe even $80 a barrel," said Eugen Weinberg, head of commodities research at Commerzbank in Frankfurt.
Russia's most powerful oil official Igor Sechin said oil prices could fall to $60 or below by the end of the first half of next year. If prices remained low, Russia had the potential to cut between 200,000 and 300,000 barrels per day of production, Sechin said.
No. But they would more than likely hire someone to assess that before a buyout/partnership/merger. The study is FDA approved.
My belief all along has been the BioImage study is really what Abbott wants. Galectine 3 is the "carrot". Abbott has the money and resources to which they can put several new diagnostic products on their automated platform using information from the BioImage study.
From recent 10Q filing "We have exclusive rights to diagnostic inventions arising from our analysis of data generated from the BioImage Study, a proprietary observational and community-based cohort of over 6,800 individuals who have been followed since 2009. Baseline blood serum, plasma, and DNA and RNA samples collected from all participants have been stored and are available for our analysis. In addition, insurance claims data, including information regarding diagnoses, procedures, and therapies related to over 1,200 non-fatal cardiovascular events that were experienced by participants in the cohort over the more than four years since follow-up was initiated is available to us for data mining. We believe that this asset provides us with a unique and proprietary platform from which we may develop new diagnostic products."